Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

305 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First clinical study of a pegylated diabody 124I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers.
Scott AM, Akhurst T, Lee FT, Ciprotti M, Davis ID, Weickhardt AJ, Gan HK, Hicks RJ, Lee ST, Kocovski P, Guo N, Oh M, Mileshkin L, Williams S, Murphy D, Pathmaraj K, O'Keefe GJ, Gong SJ, Pedersen JS, Scott FE, Wheatcroft MP, Hudson PJ. Scott AM, et al. Among authors: mileshkin l. Theranostics. 2020 Sep 15;10(25):11404-11415. doi: 10.7150/thno.49422. eCollection 2020. Theranostics. 2020. PMID: 33052222 Free PMC article. Clinical Trial.
In vivo tracking of dendritic cells in patients with multiple myeloma.
Prince HM, Wall DM, Ritchie D, Honemann D, Harrrison S, Quach H, Thompson M, Hicks R, Lau E, Davison J, Loudovaris M, Moloney J, Loveland B, Bartholeyns J, Katsifis A, Mileshkin L. Prince HM, et al. Among authors: mileshkin l. J Immunother. 2008 Feb-Mar;31(2):166-79. doi: 10.1097/CJI.0b013e31815c5153. J Immunother. 2008. PMID: 18481386
The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum.
Westwood JA, Murray WK, Trivett M, Haynes NM, Solomon B, Mileshkin L, Ball D, Michael M, Burman A, Mayura-Guru P, Trapani JA, Peinert S, Hönemann D, Miles Prince H, Scott AM, Smyth MJ, Darcy PK, Kershaw MH. Westwood JA, et al. Among authors: mileshkin l. J Immunother. 2009 Apr;32(3):292-301. doi: 10.1097/CJI.0b013e31819b7c8e. J Immunother. 2009. PMID: 19242371
Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer.
Binns DS, Pirzkall A, Yu W, Callahan J, Mileshkin L, Conti P, Scott AM, Macfarlane D, Fine BM, Hicks RJ; OSI3926g Study Team. Binns DS, et al. Among authors: mileshkin l. Eur J Nucl Med Mol Imaging. 2011 Apr;38(4):642-50. doi: 10.1007/s00259-010-1665-0. Epub 2011 Jan 5. Eur J Nucl Med Mol Imaging. 2011. PMID: 21207024 Clinical Trial.
Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011. Australian Consensus Guidelines 2011 Steering Committee.
Lingaratnam S, Slavin MA, Koczwara B, Seymour JF, Szer J, Underhill C, Prince M, Mileshkin L, O'Reilly M, Kirsa SW, Bennett CA, Davis ID, Morrissey O, Thursky KA; Australian Consensus Guidelines 2011 Steering Committee. Lingaratnam S, et al. Among authors: mileshkin l. Intern Med J. 2011 Jan;41(1b):75-81. doi: 10.1111/j.1445-5994.2010.02338.x. Intern Med J. 2011. PMID: 21272171
Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
Mileshkin L, Hicks RJ, Hughes BG, Mitchell PL, Charu V, Gitlitz BJ, Macfarlane D, Solomon B, Amler LC, Yu W, Pirzkall A, Fine BM. Mileshkin L, et al. Clin Cancer Res. 2011 May 15;17(10):3304-15. doi: 10.1158/1078-0432.CCR-10-2763. Epub 2011 Mar 1. Clin Cancer Res. 2011. PMID: 21364032 Clinical Trial.
305 results